miR-139抗肿瘤作用与机制

摘要/Abstract

摘要：微小RNA（miRNA）与肿瘤的发生发展密切相关。miR139是一种具有抑癌作用的miRNA分子，在多种肿瘤组织中表达降低，而过表达miR-139可通过多种靶基因抑制肿瘤细胞的增殖、迁移和侵袭，并诱导其凋亡。因此，miR139在肿瘤的临床诊断、治疗及预后判断等方面具有潜在的应用前景。

翟俊山,李楠. miR-139抗肿瘤作用与机制[J]. 国际肿瘤学杂志, 2016, 43(10): 765-768.

Zhai Junshan, Li Nan. Anticancer effect and mechanism of miR-139[J]. Journal of International Oncology, 2016, 43(10): 765-768.

［1］ Liu B, Li J, Cairns MJ. Identifying miRNAs, targets and functions［J］. Brief Bioinform, 2014, 15(1): 1-19. DOI: 10.1093/bib/bbs075. ［2］ Sun C, Sang M, Li S, et al. HsamiR1395p inhibits proliferation and causes apoptosis associated with downregulation of cMet［J］. Oncotarget, 2015, 6(37): 39756-39792. DOI: 10.18632/oncotarget.5476. ［3］ Radfar MH, Wong W, Morris Q. Computational prediction of intronic microRNA targets using host gene expression reveals novel regulatory mechanisms［J］. PLoS One, 2011, 6(6): e19312. DOI: 10.1371/journal.pone.0019312. ［4］ Ozsolak F, Poling LL, Wang Z, et al. Chromatin structure analyses identify miRNA promoters［J］. Genes Dev, 2008, 22(22): 3172-3183. DOI: 10.1101/gad.1706508. ［5］ Shen K, Mao R, Ma L, et al. Posttranscriptional regulation of the tumor suppressor miR1395p and a network of miR1395pmediated mRNA interactions in colorectal cancer［J］. FEBS J, 2014, 281(16): 3609-3624. DOI: 10.1111/febs.12880. ［6］ Bao W, Fu HJ, Xie QS, et al. HER2 interacts with CD44 to upregulate CXCR4 via epigenetic silencing of microRNA139 in gastric cancer cells［J］. Gastroenterology, 2011, 141(6): 2076-2087.e6. DOI: 10.1053/j.gastro.2011.08.050. ［7］ Watanabe K, Amano Y, Ishikawa R, et al. Histone methylationmediated silencing of miR139 enhances invasion of nonsmallcell lung cancer［J］. Cancer Med, 2015, 4(10): 1573-1582. DOI: 10.1002/cam4.505. ［8］ Zhang L, Dong Y, Zhu N, et al. microRNA1395p exerts tumor suppressor function by targeting NOTCH1 in colorectal cancer［J］. Mol Cancer, 2014, 13: 124. DOI: 10.1186/1476459813124. ［9］ Guo H, Hu X, Ge S, et al. Regulation of RAP1B by miR139 suppresses human colorectal carcinoma cell proliferation［J］. Int J Biochem Cell Biol, 2012, 44(9): 1465-1472. DOI: 10.1016/j.biocel.2012.05.015. ［10］ Shen K, Liang Q, Xu K, et al. MiR139 inhibits invasion and metastasis of colorectal cancer by targeting the type Ⅰ insulinlike growth factor receptor［J］. Biochem Pharmacol, 2012, 84(3): 320-330. DOI: 10.1016/j.bcp.2012.04.017. ［11］ Song M, Yin Y, Zhang J, et al. MiR1395p inhibits migration and invasion of colorectal cancer by downregulating AMFR and NOTCH1［J］. Protein Cell, 2014, 5(11): 851-861. DOI: 10.1007/s1323801400935. ［12］ Wong CC, Wong CM, Tung EK, et al. The microRNA miR139 suppresses metastasis and progression of hepatocellular carcinoma by downregulating Rhokinase 2［J］. Gastroenterology, 2011, 140(1): 322-331. DOI: 10.1053/j.gastro.2010.10.006. ［13］ Fan Q, He M, Deng X, et al. Derepression of cFos caused by microRNA139 downregulation contributes to the metastasis of human hepatocellular carcinoma［J］. Cell Biochem Funct, 2013, 31(4): 319-324. DOI: 10.1002/cbf.2902. ［14］ Gu W, Li X, Wang J. miR139 regulates the proliferation and invasion of hepatocellular carcinoma through the WNT/TCF4 pathway［J］. Oncol Rep, 2014, 31(1): 397-404. DOI: 10.3892/or.2013.2831. ［15］ Qiu G, Lin Y, Zhang H, et al. miR1395p inhibits epithelialmesenchymal transition, migration and invasion of hepatocellular carcinoma cells by targeting ZEB1 and ZEB2［J］. Biochem Biophys Res Commun, 2015, 463(3): 315-321. DOI: 10.1016/j.bbrc.2015.05.062. ［16］ Guo J, Miao Y, Xiao B, et al. Differential expression of microRNA species in human gastric cancer versus nontumorous tissues［J］. J Gastroenterol Hepatol, 2009, 24(4): 652-657. DOI: 10.1111/j.14401746.2008.05666.x. ［17］ Kang HS, Kim J, Jang SG, et al. MicroRNA signature for HER2positive breast and gastric cancer［J］. Anticancer Res, 2014, 34(7): 3807-3810. . ［18］ Zhang Y, Shen WL, Shi ML, et al. Involvement of aberrant miR139/Jun feedback loop in human gastric cancer［J］. Biochim Biophys Acta, 2015, 1853(2): 481-488. DOI: DOI: 10.1016/j.bbamcr.2014.12.002. ［19］ Krishnan K, Steptoe AL, Martin HC, et al. miR1395p is a regulator of metastatic pathways in breast cancer［J］. RNA, 2013, 19(12): 1767-1780. DOI: 10.1261/rna.042143.113. ［20］ Rask L, Balslev E, Skilde R, et al. Differential expression of miR139, miR486 and miR21 in breast cancer patients subclassified according to lymph node status［J］. Cell Oncol (Dordr), 2014, 37(3): 215-227. DOI: 10.1007/s1340201401766. ［21］ Hua W, Sa KD, Zhang X, et al. MicroRNA139 suppresses proliferation in luminal type breast cancer cells by targeting topoisomerase Ⅱ alpha［J］. Biochem Biophys Res Commun, 2015, 463(4): 1077-1083. DOI: 10.1016/j.bbrc.2015.06.061. ［22］ Zhang HD, Sun DW, Mao L, et al. MiR1395p inhibits the biological function of breast cancer cells by targeting Notch1 and mediates chemosensitivity to docetaxel［J］. Biochem Biophys Res Commun, 2015, 465(4): 702-713. DOI: 10.1016/j.bbrc.2015.08.053. ［23］ Luo HN, Wang ZH, Sheng Y, et al. MiR139 targets CXCR4 and inhibits the proliferation and metastasis of laryngeal squamous carcinoma cells［J］. Med Oncol, 2014, 31(1): 789. DOI: 10.1007/s120320130789z. ［24］ Liu R, Yang M, Meng Y, et al. Tumorsuppressive function of miR1395p in esophageal squamous cell carcinoma［J］. PLoS One, 2013, 8(10): e77068. DOI: 10.1371/journal.pone.0077068. ［25］ Dai S, Wang X, Li X, et al. MicroRNA1395p acts as a tumor suppressor by targeting ELTD1 and regulating cell cycle in glioblastoma multiforme［J］. Biochem Biophys Res Commun, 2015, 467(2): 204-210. DOI: 10.1016/j.bbrc.2015.10.006. ［26］ Emmrich S, Engeland F, ElKhatib M, et al. miR1395p controls translation in myeloid leukemia through EIF4G2［J］. Oncogene, 2016, 35(14): 1822-1831. DOI: 10.1038/onc.2015.247. ［27］ Zhang HD, Jiang LH, Sun DW, et al. MiR1395p: promising biomarker for cancer［J］. Tumour Biol, 2015, 36(3): 1355-1365. DOI: 10.1007/s1327701531993.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲.血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华.Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青.血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺.PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云.新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六.基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅.基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳.炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志.宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.

Anticancer effect and mechanism of miR-139

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章15

编辑推荐

Metrics

本文评价